BAXTER HEALTHCARE CORPORATION for BAXTER HEALTHCARE CORPORATION
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Issues related to pharmaceutical pricing. Issues related to drug shortages. Issues related to implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CADE CLURMAN | — |
| JACK MANIKO | — |
Health Issues HCR
Issues relating to drug pricing, 340B Drug pricing Issues relating to safe mobility and issues relating to diabetic retinopathy. Issues relating to pandemic preparedness act. Issues related to artificial intelligence technology in healthcare; Issues around emergency preparedness and critical medical supplies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CADE CLURMAN | — |
| JACK MANIKO | — |
Budget/Appropriations BUD
Issues related to increasing funding for Strategic National Stockpile. Labor, Health, and Human Services appropriations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CADE CLURMAN | — |
| JACK MANIKO | — |
Taxation/Internal Revenue Code TAX
Taxation of multinational companies. Monitor tax reform proposal relating to corporate tax policies. Issues related to implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CADE CLURMAN | — |
Defense DEF
S. 4784, the FY27 National Defense Authorization Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| CADE CLURMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.